Capricor Therapeutics to Present Results from the HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at the International World Muscle Society Virtual Congress 2020

--Final 12-Month Results from Phase II Trial to be Presented on October 1--

LOS ANGELES, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announced today that the Company will present novel data from its randomized, double-blind, Phase II HOPE-2 clinical trial with its lead investigational product, CAP-1002, in boys and young men with Duchenne muscular dystrophy (DMD).

Click to view original post

Capricor Therapeutics to Present Results from the HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at the International World Muscle Society Virtual Congress 2020

--Final 12-Month Results from Phase II Trial to be Presented on October 1--

LOS ANGELES, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announced today that the Company will present novel data from its randomized, double-blind, Phase II HOPE-2 clinical trial with its lead investigational product, CAP-1002, in boys and young men with Duchenne muscular dystrophy (DMD).

Click to view original post